[go: up one dir, main page]

FI906204L - Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi - Google Patents

Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi Download PDF

Info

Publication number
FI906204L
FI906204L FI906204A FI906204A FI906204L FI 906204 L FI906204 L FI 906204L FI 906204 A FI906204 A FI 906204A FI 906204 A FI906204 A FI 906204A FI 906204 L FI906204 L FI 906204L
Authority
FI
Finland
Prior art keywords
pharmaceutically active
active peptide
peptide compounds
preparing pharmaceutically
preparing
Prior art date
Application number
FI906204A
Other languages
English (en)
Swedish (sv)
Other versions
FI93548B (fi
FI906204A0 (fi
FI93548C (fi
Inventor
Masaaki Matsuo
Daijiro Hagiwara
Hiroshi Miyake
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of FI906204A0 publication Critical patent/FI906204A0/fi
Publication of FI906204L publication Critical patent/FI906204L/fi
Publication of FI93548B publication Critical patent/FI93548B/fi
Application granted granted Critical
Publication of FI93548C publication Critical patent/FI93548C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI906204A 1989-12-22 1990-12-17 Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi FI93548C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8929070 1989-12-22
GB898929070A GB8929070D0 (en) 1989-12-22 1989-12-22 Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same

Publications (4)

Publication Number Publication Date
FI906204A0 FI906204A0 (fi) 1990-12-17
FI906204L true FI906204L (fi) 1991-06-23
FI93548B FI93548B (fi) 1995-01-13
FI93548C FI93548C (fi) 1995-04-25

Family

ID=10668423

Family Applications (1)

Application Number Title Priority Date Filing Date
FI906204A FI93548C (fi) 1989-12-22 1990-12-17 Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi

Country Status (21)

Country Link
US (1) US5468731A (fi)
EP (1) EP0443132B1 (fi)
JP (1) JP2560919B2 (fi)
KR (1) KR0180223B1 (fi)
CN (2) CN1034869C (fi)
AT (1) ATE98651T1 (fi)
AU (1) AU640185B2 (fi)
CA (1) CA2032864C (fi)
DE (1) DE69005286T2 (fi)
DK (1) DK0443132T3 (fi)
ES (1) ES2060910T3 (fi)
FI (1) FI93548C (fi)
GB (1) GB8929070D0 (fi)
HK (1) HK18696A (fi)
HU (2) HUT56581A (fi)
IE (1) IE64570B1 (fi)
NO (1) NO177535C (fi)
PT (1) PT96324B (fi)
RU (1) RU2055078C1 (fi)
UA (1) UA27254C2 (fi)
ZA (1) ZA909901B (fi)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420297A (en) * 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5654400A (en) * 1991-10-04 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Process for making peptide compounds having tachykinin antagonistic activity
CA2324959C (en) * 1991-11-12 2002-11-12 Pfizer Limited Phthalimido compounds as intermediates for producing substance p receptor antagonists
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
DK0655055T3 (da) * 1992-08-13 2001-01-02 Warner Lambert Co Tachykininantagonister
ES2137998T3 (es) * 1992-09-03 2000-01-01 Boehringer Ingelheim Pharma Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
DE4243496A1 (de) * 1992-09-03 1994-03-10 Boehringer Ingelheim Kg Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
WO1994020126A1 (en) * 1993-03-03 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Use of peptides for the manufacture of a medicament
WO1995000536A1 (en) * 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
EP0719561A4 (en) * 1993-08-10 1997-07-30 Fujisawa Pharmaceutical Co Percutaneous absorbent preparation
EP1736152A3 (en) * 1993-10-29 2009-10-07 The Trustees Of Boston University Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
ITFI940009A1 (it) * 1994-01-19 1995-07-19 Menarini Farma Ind Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
KR100344607B1 (ko) * 1994-03-17 2002-11-20 후지레비오 가부시끼가이샤 아자펩티드유도체
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
MX9605128A (es) * 1994-05-07 1997-08-30 Boehringer Ingelheim Kg Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
US5966295A (en) * 1994-12-27 1999-10-12 Autonics Corporation Convertible flush or exposure type terminal board of control device
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
GB9700597D0 (en) * 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
JP2001524960A (ja) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド 摂食障害を治療するためのｎｋ−１受容体拮抗薬の使用
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007376A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298779A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
US6441131B1 (en) * 1997-12-22 2002-08-27 Ono Pharmaceutical Co., Ltd. Peptides, method for assaying human pepsinogen II or human pepsin II, and assaying kit
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
WO1999064395A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
AU2180600A (en) * 1998-12-18 2000-07-12 Warner-Lambert Company Non-peptide nk1 receptors antagonists
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
PL366425A1 (en) * 2001-01-02 2005-01-24 Fujisawa Pharmaceutical Co, Ltd. Peptide compounds
US20050070480A1 (en) * 2001-08-21 2005-03-31 Sandor Bajusz Peptide arginals and methods for treating disseminated intravascular coagulation
KR100960802B1 (ko) 2003-03-08 2010-06-01 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
AU2010225747A1 (en) 2009-03-17 2011-11-10 Daiichi Sankyo Company,Limited Amide derivative
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EA020553B1 (ru) 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (fi) 2011-04-21 2015-06-12 Piramal Entpr Ltd
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018013962A1 (en) 2016-07-15 2018-01-18 Viracta Therapeutics, Inc. Histone deacetylase inhibitors for use in immunotherapy
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
MA53287A (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Inhibiteurs de prmt5
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
US5187156A (en) * 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
DE3818850A1 (de) * 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
DE3913272A1 (de) * 1989-04-22 1990-10-25 Hoechst Ag Dipeptid-derivate mit enzym-inhibitorischer wirkung
DE3913290A1 (de) * 1989-04-22 1990-10-25 Hoechst Ag Renin-hemmende di- und tripeptide, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
WO1991012266A1 (fr) * 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Compose peptidique

Also Published As

Publication number Publication date
KR0180223B1 (ko) 1999-04-01
HU908443D0 (en) 1991-07-29
HK18696A (en) 1996-02-09
CA2032864C (en) 2003-05-06
DK0443132T3 (da) 1994-01-24
IE904581A1 (en) 1991-07-03
EP0443132B1 (en) 1993-12-15
DE69005286D1 (de) 1994-01-27
US5468731A (en) 1995-11-21
CN1034869C (zh) 1997-05-14
HUT56581A (en) 1991-09-30
GB8929070D0 (en) 1990-02-28
ZA909901B (en) 1991-10-30
AU6801090A (en) 1991-06-27
ES2060910T3 (es) 1994-12-01
DE69005286T2 (de) 1994-04-21
NO177535B (no) 1995-06-26
EP0443132A1 (en) 1991-08-28
CA2032864A1 (en) 1991-06-23
HU211558A9 (en) 1995-12-28
NO905572D0 (no) 1990-12-21
NO177535C (no) 1995-10-04
CN1159949A (zh) 1997-09-24
FI93548B (fi) 1995-01-13
UA27254C2 (uk) 2000-08-15
FI906204A0 (fi) 1990-12-17
PT96324B (pt) 1998-10-30
AU640185B2 (en) 1993-08-19
JP2560919B2 (ja) 1996-12-04
FI93548C (fi) 1995-04-25
CN1064080A (zh) 1992-09-02
KR910011891A (ko) 1991-08-07
NO905572L (no) 1991-06-24
JPH04210996A (ja) 1992-08-03
PT96324A (pt) 1991-09-30
ATE98651T1 (de) 1994-01-15
IE64570B1 (en) 1995-08-23
RU2055078C1 (ru) 1996-02-27

Similar Documents

Publication Publication Date Title
FI906204L (fi) Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi
FI860484L (fi) Menetelmä terapeuttisesti aktiivisten peptidijohdannaisten valmistamiseksi
FI870903L (fi) Menetelmä terapeuttisesti aktiivisten alfa-heterosykleillä substituoitujen tolunitriilien valmistamiseksi
FI890652A7 (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
FI945465L (fi) Menetelmä hidastetusti vapauttavien lääkevalmisteiden valmistamiseksi
FI883050L (fi) Menetelmä terapeuttisesti aktiivisten pyranoindolitsinokinoliinijohdannaisten valmistamiseksi
NO176759C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater
KR910700249A (ko) 신규 치료학적 활성 화합물 및 그의 제조 방법
FI890282L (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI963424L (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
IS3529A7 (is) Hliðstæð aðferð við framleiðslu á meðferðarvirkum bis-aza-bísýklískum efnasamböndum
FI892497L (fi) Menetelmä terapeuttisesti aktiivisten bentsamidijohdannaisten valmistamiseksi
FI891361A7 (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
FI922815L (fi) Menetelmä uusien farmaseuttisesti aktiivisten D-vitamiinianalogien valmistamiseksi
FI890123L (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia indolyylipiperidiiniyhdisteitä
FI892185L (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidiyhdisteiden valmistamiseksi
NO173784C (no) Anaslogifremgangsmaate for fremstilling av terapeutisk aktive tieno-tri-azolo-diazepinderivater
FI924642L (fi) Menetelmä terapeuttisesti aktiivisten 3-indolyylitioasetaattijohdannaisten valmistamiseksi
FI916058A7 (fi) Menetelmä terapeuttisesti aktiivisten dihydrobentsofuraanikarboksamidien valmistamiseksi
FI884660L (fi) Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi
FI874789L (fi) Menetelmä valmistaa farmakologisesti aktiivisia substituoituja 1H-imidatsoleja
FI912868A7 (fi) Menetelmä farmaseuttisten yhdisteiden valmistamiseksi
NO174200C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser
FI893002L (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi
FI880103L (fi) Menetelmä terapeuttisesti aktiivisen sialosyylikolesterolin valmistamiseksi

Legal Events

Date Code Title Description
FG Patent granted

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.

BB Publication of examined application
FG Patent granted

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.

MA Patent expired